This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,078,081 to support the development of a novel, first-in-class small molecule antagonist to the retinoic acid receptor-alpha (RAR) that regulates the induction of gut-homing receptors on activated T cells. The award to Orphagen Pharmaceuticals, Inc. aims to advance this promising therapeutic approach for the treatment of inflammatory bowel disease (IBD), which affects the gut. Preliminary data have shown the RAR antagonist can improve gut histology and inhibit the accumulation of inflammatory T cells in the colon in animal models. The project period runs from Sep 15, 2024 to Jul 31, 2026.
Generated 1/28/25, 10:56 AM